Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference

Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference




Clover Health to Participate in Upcoming 2025 UBS Global Healthcare Conference

WILMINGTON, Del., Oct. 22, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 11:00 a.m. Eastern Time.

A live webcast and replay of the presentation will be accessible on Clover Health’s investor relations website at https://investors.cloverhealth.com/.

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease




Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).

During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.

Webcast Details:

Date: Tuesday, October 28, 2025
Time: 4:30 PM Eastern Time

Access: 

  • Listen Only: Listeners can register for the webcast via this LINK
  • Listen and Live Q&A: Analysts or investors wishing to participate in the Q&A session should use this LINK

Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion and will remain available for a period of 30 days.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease




Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).

During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.

Webcast Details:

Date: Tuesday, October 28, 2025
Time: 4:30 PM Eastern Time

Access: 

  • Listen Only: Listeners can register for the webcast via this LINK
  • Listen and Live Q&A: Analysts or investors wishing to participate in the Q&A session should use this LINK

Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion and will remain available for a period of 30 days.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

Generation Bio Announces CEO Transition

Generation Bio Announces CEO Transition




Generation Bio Announces CEO Transition

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors

• Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President

CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company’s Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company’s Chief Legal Officer since joining in April 2023. Jason Rhodes will step down as Chair of the Board and will remain a Board Director. These changes will be effective October 31, 2025.

“Geoff has been instrumental in building Generation Bio, and we look forward to his leadership as Board Chair.” said Jason Rhodes, former Board Chair of Generation Bio. “We have the highest confidence in Yalonda’s ability to lead Generation Bio in her new role during this time of transition for the company.”

About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit www.generationbio.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company’s leadership transition, the company’s strategic alternatives process, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties as to the company’s ability to successfully pursue a strategic alternative transaction on attractive terms, or at all; whether the chief executive officer transition will be successful; as well as the other risks and uncertainties set forth in the “Risk Factors” section of the company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.

Investors and Media Contact
Kevin Conway
Generation Bio
investors@generationbio.com
(857) 371-4721

Generation Bio Announces CEO Transition

Generation Bio Announces CEO Transition




Generation Bio Announces CEO Transition

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors

• Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President

CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company’s Board of Directors. The Board has appointed Yalonda Howze, JD, as Interim Chief Executive Officer and President. Ms. Howze has served as the Company’s Chief Legal Officer since joining in April 2023. Jason Rhodes will step down as Chair of the Board and will remain a Board Director. These changes will be effective October 31, 2025.

“Geoff has been instrumental in building Generation Bio, and we look forward to his leadership as Board Chair.” said Jason Rhodes, former Board Chair of Generation Bio. “We have the highest confidence in Yalonda’s ability to lead Generation Bio in her new role during this time of transition for the company.”

About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit www.generationbio.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the company, including statements about the company’s leadership transition, the company’s strategic alternatives process, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties as to the company’s ability to successfully pursue a strategic alternative transaction on attractive terms, or at all; whether the chief executive officer transition will be successful; as well as the other risks and uncertainties set forth in the “Risk Factors” section of the company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.

Investors and Media Contact
Kevin Conway
Generation Bio
investors@generationbio.com
(857) 371-4721

Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025

Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025




Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025

FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com

EmblemHealth Celebrating Strong Leadership in Challenging Times

EmblemHealth Celebrating Strong Leadership in Challenging Times




EmblemHealth Celebrating Strong Leadership in Challenging Times

EmblemHealth Hosts Annual Heroes of Labor Awards

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — EmblemHealth, a not-for-profit health plan dedicated to its community mission, and LaborPress, New York’s top source for daily labor news and industry information, are proud to present the annual Heroes of Labor Awards. With a legacy of over 85 years serving New York communities, EmblemHealth demonstrates a steadfast commitment to supporting labor union members, working individuals, and government and municipal employees.

“The challenges and uncertainty working families face daily are growing, and these times call for strong leadership,” stated Christine O’Connor, Assistant-Vice President for New York City Strategic Relations. “We are fortunate to have exemplary leaders who are meeting this moment, and we celebrate their accomplishments.”

This year’s honorees are:

  • Joseph Colangelo, SEIU Local 246 President
  • Dilcy Benn, District Council 37 Local 1505
  • James Brosi, President of UFOA-IAFF Local 854

“Labor makes up the solid foundation of the metropolis we call home,” said Neal Tepel, Labor Press Publisher. “As our great city faces turbulent headwinds from the Federal Government, our award winners stand firm today and every day, because without them, there is no New York.”

Heroes of Labor began in 2012 in response to the exemplary work done by union leaders and members in the aftermath of Hurricane Sandy. These awards have been a tribute to the everyday champions of New York City. This event marks the dedication of working men and women across the city who strive to keep our city strong.

About EmblemHealth
EmblemHealth is one of the nation’s largest not-for-profit health insurers, serving members across New York’s diverse communities with a full range of commercial and government-sponsored health plans for employers, individuals, and families. With a commitment to value-based care, EmblemHealth partners with top hospitals and doctors, including its own AdvantageCare Physicians, to deliver quality, affordable, convenient care. At more than a dozen EmblemHealth Neighborhood Care locations, members and nonmembers have access to community-based health and wellness guidance and resources. For more information, visit emblemhealth.com.

Contact: 
EmblemHealth Public Relations Office | Email: press@emblemhealth.com

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025




I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

  • Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3W
  • No differences in efficacy were observed across different CLDN18.2 expression levels, with favorable overall safety
  • Data anchor combination clinical strategy in first line (1L) gastric cancer, a $2B potential market1
  • Confirming Q1 2026 plans to report topline Phase 1b dose expansion combination data and initiate a global randomized Phase 2 study
  • Data slated for “Short Talk” presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (the Triple Meeting) underway October 22-26 in Boston, Massachusetts

ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, today announced that updated data from the Phase 1 study (NCT04900818) of givastomig as a monotherapy in heavily pre-treated patients (n=45) with gastroesophageal carcinoma (GEC) will be presented as a “short-talk” at the Triple Meeting on October 23, 2025 in Boston, Massachusetts (Presentation #B016). Givastomig is a bispecific antibody targeting CLDN18.2 (Claudin 18.2) and 4-1BB.

“The Phase 1 givastomig monotherapy data that will be shared at the Triple Meeting continue to demonstrate impressive safety and efficacy, with an 18% ORR in heavily pre-treated gastric cancer patients, with favorable overall safety. These data, showing responses over a dose range from 5 mg/kg Q2W to 18 mg/kg Q3W, further enrich givastomig’s emerging product profile and bolster our confidence that givastomig has the potential to be a best-in-class Claudin18.2-directed therapy across a broad range of CLDN18.2 expression. In Q1 2026, we expect to report topline results from the fully-enrolled Phase 1b dose expansion immune-chemotherapy combination study and initiate a global, randomized Phase 2 combination study. We believe the data from these studies will clearly demonstrate givastomig’s potential to significantly improve the standard of care in the treatment of first line GEC patients with a broad range of Claudin 18.2 expression levels,” said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab.

“In our experience, givastomig integrates well into the workflow at our center. Based on the monotherapy efficacy across a range of doses and Claudin 18.2 expression levels, and excellent overall safety, givastomig has the potential to be the best-in-class Claudin-directed therapy and combination partner for the treatment of frontline gastric cancer. These follow-up data, plus encouraging initial results from the Phase 1b immune-chemotherapy frontline combination studies, presented earlier this year, give us hope that givastomig treatment can lead to improved treatment outcomes for patients with gastric cancers. We are eager to move forward with the planned Phase 2 study and continue to advance this program,” said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital.

AACR-NCI-EORTC “the Triple Meeting” Conference Information:

Title: Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)

Session: Concurrent Session 2: Bispecifics/T-cell Engagers

Speaker: Samuel J. Klempner, MD, Associate Professor of Medicine, Massachusetts General Hospital

Presentation Number: B016

Date and Time: Thursday, October 23, 2025, 6:20 – 6:35 PM ET

Location: Hynes Convention Center

A copy of the Triple Meeting presentation and poster will be available on the Publications and Presentations page of the I-Mab website on October 23, 2025.

Givastomig Phase 1 Monotherapy Updated data Summary GEC (per June 10, 2025 data cut-off):

  • Givastomig was well tolerated up to 15 mg/kg Q2W and 18 mg/kg Q3W and continues to show monotherapy activity in heavily pre-treated GEC patients with a wide range of CLDN18.2 expression
  • Givastomig may have the ability to target patients with lower CLDN18.2 expression compared with other CLDN18.2 agents

Patients Characteristics:

  • 45 GEC patients were dosed with givastomig every two weeks (Q2W) across dose levels of: 5mg/kg (n=7), 8 mg/kg (n=5), 12 mg/kg (n=21), 15 mg/kg (n=6) and 18 mg/kg Q3W (n=6) as of the June 10, 2025 data cutoff
  • Patients had received a median of 3 prior therapies including 74% with a prior PD-L1 inhibitor

Efficacy Results:

  • Confirmed Objective Response Rate (ORR):
    • 18% of patients (8/45) achieved a partial response (PR)
      • 5 mg/kg (1/7)
      • 8 mg/kg (1/5)
      • 12 mg/kg (4/21)
      • 15 mg (0/6)
      • 18 mg/kg Q3W (2/6)
    • Claudin 18.2 expression in responders ranged from 11% (1+, 10%; 2+, 1%) to 100% (2+, 10%; 3+, 90%)
  • The Disease Control Rate (DCR) was 49%, including stable disease (SD) in 14 patients

Follow-up and Biomarker Data:

  • 2 patients are ongoing (4%), with 1 PR (8 mg/kg) at 33 months (mo), and 1 PR (18 mg/kg Q3W) at 10 mo
  • The median progression free survival (mPFS) and median overall survival (mOS) are 2.96 mo (95% CI 1.71-3.91) and 7.49 mo (95% CI 4.96-12.5), respectively
  • No statistical difference in ORR, DCR, PFS or OS, between CLDN18.2-high (n=21) and CLDN18.2-low patients (n=24): ORR 19% v. 17% (p=1.00), DCR 57% v. 42% (p=0.46), mPFS 3.68 mo v. 1.84 mo, PFS hazard ratio (HR) 0.87 (p=0.67), and mOS 7.49 mo v. 7.49 mo, OS HR 0.88 (p=0.74), respectively

Safety:

  • There were no new safety signals identified with longer follow-up
  • No dose limiting toxicities were observed
  • Common TREAEs (≥15%, any grade/grade 3) included anemia (27%/9%), white blood cell count decrease (22%/7%), nausea (20%/2%), ALT increase (16%/2%) and AST increase (16%/4%)

About Givastomig

Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents.

Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.

Sources

  1. Proprietary I-Mab information, 2025

About I-Mab

I-Mab (NASDAQ: IMAB) is a global biotechnology platform company committed to accelerating access to innovative medicines. We combine deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, I-Mab enables transformative therapies to progress rapidly from discovery toward patients in need. Following this business model change, on October 16, 2025, the Company announced that it intends to change its name to NovaBridge Bioscience, subject to Extraordinary General Meeting (EGM) approval on October 24, 2025.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB), and, pending acquisition, VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. I-Mab is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, I-Mab owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a large, randomized, dose-ranging Phase 2 study for wet AMD. Following completion of the pending acquisition and formation of the new Visara, Inc. subsidiary, I-Mab will be the majority shareholder of Visara, and Visara will control global rights to VIS-101.

For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential benefits of the new corporate strategy, the pending VIS-101 acquisition, and the planned capitalization of Visara, the expected approval of shareholder proposals at the upcoming EGM, the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates, the strategic and clinical development of I-Mab’s drug candidates, including givastomig and VIS-101; anticipated clinical milestones and results, and related timing; and the Company’s anticipated cash runway. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in I-Mab’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

I-Mab Investor & Media Contacts

PJ Kelleher  Kyler Lei
LifeSci Advisors  I-Mab
+1-617-430-7579  +1-240-745-6330
pkelleher@lifesciadvisors.com  kyler.lei@imabbio.com
  IR@imabbio.com

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor




Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior KRAS(OFF) G12C inhibitor. These results will be highlighted in an oral presentation at the AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Boston, October 23-25.

“The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS(ON) G12C-selective inhibitor, including in patients who have progressed on G12C(OFF) inhibitors,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “These findings reinforce the promise of our RAS(ON) inhibitor platform to deliver a range of therapies that target the active, GTP-bound state of RAS proteins with the potential to create new global standards of care.”

As of the August 4, 2025 data cutoff date, patients with KRAS G12C NSCLC, who had received prior therapy with a KRAS(OFF) G12C inhibitor, were treated with elironrasib at the recommended Phase 2 dose of 200 mg orally twice daily (BID) and were evaluated on key safety and antitumor activity endpoints. These patients (n=24) were heavily pretreated, with a median of three prior lines of therapy (range 2-6), with 92% (22 out of 24 patients) having progressed on a prior KRAS(OFF) G12C inhibitor.​ Elironrasib demonstrated compelling antitumor activity, with a confirmed objective response rate of 42% (95% CI: 22-63) and a disease control rate of 79% (95% CI: 58-93). The median duration of response was 11.2 months (95% CI: 5.9-not estimable), and the median progression-free survival was 6.2 months (95% CI: 4.0-10.3). The median overall survival (OS) was not yet reached and 12-month OS rate was 62% (95% CI: 40-78).

These results are from RMC-6291-001, an ongoing multicenter, Phase 1 trial designed to evaluate elironrasib (RMC‑6291) monotherapy in patients with advanced KRAS G12C solid tumors.

Elironrasib is an innovative, mutant-selective inhibitor that binds selectively and covalently to the oncogenic RAS(ON) form of the RAS G12C variant that drives approximately 12% of cases of NSCLC. Revolution Medicines is exploring elironrasib monotherapy and combinations in various treatment settings and continues work to prioritize among multiple options for advancing its development. In July 2025, elironrasib was granted Breakthrough Therapy Designation for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

NSCLC accounts for 80%-85% of all lung cancers, and most patients have advanced or metastatic disease at initial diagnosis.1,2 KRAS mutations are found in nearly 30% of NSCLC cases, among which KRAS G12C is the most common.

Advancing RAS(ON) Inhibitor Platform Across Tumor Types
Jan Smith, Ph. D., chief scientific officer of Revolution Medicines will also highlight encouraging preclinical data supporting the RAS(ON) inhibitor doublet of zoldonrasib and daraxonrasib during a plenary session at the start of the AACR-NCI-EORTC Symposium.

Several other presentations to be featured at the meeting demonstrate continued progress across Revolution Medicines’ RAS(ON) inhibitor portfolio, including:

  • “Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors”
  • “RAS(ON) Inhibitor In-Pathway Combinations Maximize RAS Pathway Suppression in KRAS Mutant CRC Models”
  • “Resistance Mechanisms to Monotherapy Daraxonrasib (RMC-6236) in RAS Mutant PDAC”
  • “RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in RAS-Mutant NSCLC”

Further details and information on presentations can found on the AACR-NCI-EORTC Symposium website.

About Non-Small Cell Lung Cancer
More than 197,000 people are diagnosed with non-small cell lung cancer (NSCLC) in the U.S. each year.3 Despite treatment advancements, NSCLC remains a leading cause of cancer-related mortality worldwide, primarily due to its late-stage diagnosis and limited response to conventional therapies.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding progression of clinical studies and findings from these studies, including the safety, tolerability and antitumor activity of the company’s candidates being studied and the durability of these results; the therapeutic potential of elironrasib; and the ability of the company to deliver a range of therapies or create new standards of care. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

1 American Cancer Society. What is Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed October 2025.
2 National Cancer Institute. Non-Small Cell Lung Cancer Treatment. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. Accessed October 2025.
3 American Cancer Society. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Accessed October 2025.

Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets

Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets




Frontier Medicines Presents Preclinical Data from Three Programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets

– FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream pathways compared to sotorasib –

– FMC-220 potently and selectively restored p53 tumor suppressor function and delivered tumor regressions, including complete responses in p53 Y220C mutant preclinical models –

– FMC-242, a covalent PI3Kα/RAS breaker, shows potent anti-tumor activity, including tumor regressions in CDX and PDX models, and enhanced efficacy in combination with other therapies –

BOSTON and SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced it will present preclinical data from three of its pipeline programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets, taking place in Boston, MA, from October 22 to 26.

“Our data presented at the Triple Meeting this year is a testament to our ability to execute across programs and to the power of the Frontier Platform. Our lead program, FMC-376, directly blocks both the ON and OFF states of the G12C mutant KRAS protein, leading to a complete and durable blockade of downstream signaling. In preclinical models, this translated to robust anti-tumor activity as a single agent, and synergistic activity when combined with cetuximab,” said Kevin Webster, Ph.D., chief scientific officer of Frontier Medicines. “FMC-220 also showed significant promise, demonstrating tumor regressions in preclinical models as a single agent, and efficacy when combined with other therapeutics, including MDM2 inhibitors or DNA-damaging agents. Finally, FMC-242 demonstrated deep inhibition of the PI3Kα-RAS interaction and potent anti-tumor activity, including tumor regressions, in preclinical models. When combined with KRAS or EGFR inhibitors, FMC-242 demonstrated enhanced efficacy.”

Summary of findings:

“FMC-376, a dual inhibitor of ON+OFF states of KRAS G12C, is active in sotorasib-resistant PDX models.”

Poster Session B – Oct. 24, 12:30-4 p.m. ET

  • FMC-376 demonstrated robust anti-tumor activity across a panel of KRAS G12C-mutant, patient-derived xenograft (PDX) models of non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
  • FMC-376, as a single agent, inhibits the growth of tumors derived from sotorasib-resistant patients. Complete tumor growth inhibition was demonstrated when FMC-376 was combined with cetuximab.
  • FMC-376 led to deeper inhibition of KRAS downstream pathways, including cholesterol homeostasis, EMT, and glycolysis, than sotorasib. Combination with cetuximab demonstrated more profound inhibition of multiple pathways, including mTOR signaling and MYC target genes. 
  • The Phase 1/2 PROSPER clinical trial (NCT06244771) is currently recruiting to evaluate FMC-376 in participants with KRAS G12C cancers, regardless of prior KRAS G12C (OFF) inhibitor therapy.

“FMC-220, a highly potent and selective covalent activator of p53 Y220C, is broadly active in p53 Y220C-containing PDX models across cancer indications.”

Poster Session B – Oct. 24, 12:30-4 p.m. ET

  • FMC-220, a potential first-in-class covalent activator of p53 Y220C, is highly potent and selective in restoring p53 tumor suppressor function, delivering far more durable activation and persistent engagement of target gene promoters than noncovalent strategies.
  • FMC-220 inhibits tumor cell viability across a panel of Y220C mutant cell lines and delivers tumor regression, including complete responses in p53 Y220C mutant CDX and PDX models, regardless of histology or co-mutations. (The p53 Y220C mutation is common, occurring in ~1% of cancers).
  • FMC-220 combines effectively with other therapeutics, including MDM2 inhibitors or DNA-damaging agents.

“FMC-242, a highly potent and selective covalent breaker of the PI3Kα-RAS interaction, demonstrates improved efficacy and tolerability as monotherapy and in combination with targeted therapies in preclinical models.”

Poster Session C – Oct. 25, 12:30-4 p.m. ET

  • In CDX and PDX cell line models, inhibition of the PI3Kα-RAS interaction with FMC-242 results in potent anti-tumor activity, including tumor regressions.
  • FMC-242, when combined with KRAS or EGFR inhibitors, results in enhanced efficacy and tumor regressions in vivo.
  • Inhibition of the PI3Kα-RAS interaction did not affect insulin signaling or blood glucose levels and was well-tolerated in vivo.
  • In vitro, covalent engagement of PI3Kα resulted in inhibition of AKT activation and tumor cell viability.
  • FMC-242 is designed to be a potent, selective, orally bioavailable covalent inhibitor of the PI3Kα-RAS family interactions that can disrupt oncogenic RAS and receptor tyrosine kinase (RTK) signaling.

About FMC-376, KRAS G12C ON+OFF Inhibitor

Frontier’s lead program, FMC-376, directly targets both the ON+OFF forms of KRAS G12C with exquisite selectivity. This differentiated mechanism of action of FMC-376 offers the potential to overcome the resistance and lack of response seen with current KRAS G12C single-acting treatments. This KRAS mutation is most prevalent in people with non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC). While it has been a target of interest for many years, only recently are meaningful advances being made.

About FMC-220, p53 Y220C Activator

FMC-220 is a highly selective, covalent small molecule activator of the Y220C mutated tumor suppressor p53. It is designed to provide prolonged target residence time and persistent pharmacodynamic effects. These properties deliver tumor regression by driving senescence and tumor cell death. p53 is often referred to as the “guardian of the genome” due to its critical role in maintaining genomic stability, but it can be altered in cancer with mutations such as Y220C. The Y220C mutation destabilizes the p53 protein, impairing its tumor-suppressive functions and contributing to cancer progression. It is estimated to occur in approximately 1-2% of all cancers, with a significant presence in solid tumors such as lung, breast, and colorectal cancers, as well as other cancer types.

About FMC-242, PI3Kα/RAS Breaker
PI3Kα is the second most commonly mutated oncogene and plays an essential role in both KRAS- and RTK-driven cancers, such as colorectal, lung, and breast cancers, among others. Traditionally, PI3K inhibitors aim to block the PI3K/AKT/mTOR pathway, which can slow or stop cancer cell growth. FMC-242 is a covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS to inhibit downstream effector signaling in tumors without impacting normal functions. The mechanism of action inhibits PI3Kα/AKT effector signaling in tumors while minimizing the toxicities commonly associated with the broader class of inhibitors.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.

Media Contact
pr@frontiermeds.com